41 results about "Dextromethorphan Hydrobromide" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in human patients for treating neurological and psychiatric conditions, such as agitation associated Alzheimer's disease and / or reducing relapse of agitation in Alzheimer's disease.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention belongs to the technical field of cough relieving and phlegm eliminating medicines, and particularly relates to compound dextromethorphan hydrobromide syrup and a preparation method thereof. On the basis that the total volume of the compound dextromethorphan hydrobromide syrup is 1000L, the compound dextromethorphan hydrobromide syrup provided by the invention is prepared from the following components: 3000g of dextromethorphan hydrobromide, 20kg of guaiacol glyceryl ether, 650kg of cane sugar, 100L of 1, 2-propylene glycol, 2000g of benzoic acid, 200g of sodium benzoate, 100g of menthol, 4000mL of essence, 14000mL of ethanol, 2000mL of caramel pigment and the balance of purified water. The compound dextromethorphan hydrobromide syrup provided by the invention takes benzoic acid as a main preservative and is matched with sodium benzoate; meanwhile, the dosage ratio of all the components in the syrup is optimized, the obtained compound dextromethorphan hydrobromide syrup is good in preservative effect, and adverse reactions are reduced.

The present disclosure relates to administering in a human patient a combination of: 1) about 100 to 110 mg, about 104 to 106 mg, or about 105 mg or less of bupropion hydrochloride or a molar equivalent amount of bupropion in a free base form or another salt form; and 2) a free base form or another salt form of dextromethorphan hydrobromide or a molar equivalent amount of dextromethorphan or a molar equivalent amount of dextromethorphan or another salt form of about 40-50 mg, about 44-46 mg, or about 45 mg or less for use in the treatment of neurological and psychiatric conditions, such as agitation associated with Alzheimer's disease, and / or reducing recurrence of agitation in Alzheimer's disease.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present application relates to a method for increasing the adhesion of a slide, belonging to the technical field of biological medicine, to solve at least one of the problems in the prior art, such as poor adhesion of mycobacterium tuberculosis on the slide, easy to drop the slide in subsequent operation, serious loss of mycobacterium tuberculosis, and influence on the diagnosis rate of pulmonary tuberculosis. The dextromethorphan hydrobromide tablets and the flaxseed gum can generate a high molecular water-soluble polymer with strong positive charge adhesion under the action of a catalyst, that is, the binder described in the present application. Since mycobacterium tuberculosis is the pathogen causing tuberculosis, its surface has a large number of negative charges. Once the mycobacterium tuberculosis with negative charges on the surface contacts the binder containing a large number of positive charges, the surface of the mycobacterium tuberculosis will be quickly wrapped by the binder, forming a firm adhesion layer, and the problem of easy dropping of the slide will not occur during staining and subsequent detection.

To search for a new active ingredient that is effective in improvement, treatment, and prevention of periodontal disease, and to provide a periodontal disease preventive or therapeutic agent including the new active ingredient.SOLUTION: A periodontal disease preventive or therapeutic agent containing dextromethorphan and / or a salt thereof, an internal or external periodontal disease preventive or therapeutic medicine, and an oral composition for preventing or treating periodontal disease such as a patch, a liniment, a film, a dentifrice, a mouthwash, or a spray, are provided. As the salt of dextromethorphan, dextromethorphan hydrobromide is preferred.SELECTED DRAWING: Figure 2

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present disclosure relates to a method of treating depression and / or reducing the risk of suicide comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride (or a molar equivalent of bupropion in another form) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or a molar equivalent of dextromethorphan in another form). The combination can be administered twice a day to a person with major depressive disorder and a score of 3 or higher on the suicide ideation item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI).

The application belongs to the field of pharmaceutical chemistry and particularly relates to a preparation method of dextromethorphan hydrobromide. The method comprises the following steps: adding a reducing agent to a solution containing a compound of formula 3, adding an acid, performing a reduction reaction, obtaining a boron-containing intermediate state, and performing acid hydrolysis on the boron-containing intermediate state to obtain dextromethorphan. In the reduction reaction process for preparing dextromethorphan, sodium borohydride and an acid system are adopted, and compared with a sodium borohydride and zinc chloride system, the reaction is more complete, and the yield and purity of dextromethorphan are greatly improved. In the process for preparing dextromethorphan hydrobromide, butanone is used as a solvent, and compared with other solvents, butanone has the best refining effect, and related impurities can be effectively removed.

The invention belongs to the field of medical chemistry, and particularly relates to a preparation method of dextromethorphan hydrobromide. The method comprises the following steps: adding a reducing agent into a solution containing a compound shown as a formula 3, adding acid, carrying out reduction reaction to obtain a boron-containing intermediate state, and hydrolyzing the boron-containing intermediate state with acid to obtain dextromethorphan. In the reduction reaction process for preparing dextromethorphan, a sodium borohydride and acid system is adopted, compared with a sodium borohydride and zinc chloride system, the reaction is more thorough, and the yield and purity of dextromethorphan are greatly improved; in the dextromethorphan hydrobromide preparation process, butanone is adopted as a solvent, the refining effect of butanone is the best compared with other solvents, and related impurities can be effectively removed.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The invention relates to a dextromethorphan hydrobromide quinidine sulfate capsule and a preparation method thereof. The dextromethorphan hydrobromide quinidine sulfate capsule comprises dextromethorphan hydrobromide, quinidine sulfate, a filling agent, a disintegrating agent, a flow aid, a lubricating agent and a capsule shell. The preparation process comprises the following steps: uniformly mixing the active ingredients with part of the auxiliary materials, preparing into particles through dry granulation, adding the lubricant, mixing, and filling into capsules. According to the dextromethorphan hydrobromide quinidine sulfate capsule and the preparation method thereof, the novel crystal form of quinidine sulfate found and disclosed for the first time is adopted, under the specific prescription, the stability of a preparation composition is improved and is kept consistent with the dosage form of an original research medicine, meanwhile, the dextromethorphan hydrobromide quinidine sulfate capsule provided by the invention is simple in preparation process, the quality of products between batches and in batches is stable, and the dextromethorphan hydrobromide quinidine sulfate capsule is suitable for industrial mass production.

The invention relates to a method for increasing the adhesive force of a glass slide, belongs to the technical field of biological medicines, and is used for solving at least one of the problems that the adhesive force of mycobacterium tuberculosis on the glass slide is poor, the slide is easy to fall off in the subsequent operation, the mycobacterium tuberculosis is seriously lost, the diagnosis rate of pulmonary tuberculosis is influenced and the like in the existing method. Under the action of a catalyst, the dextromethorphan hydrobromide tablet and flaxseed gum can generate a high-molecular water-soluble polymer with strong positive charge adhesive power, namely the adhesive disclosed by the invention. Mycobacterium tuberculosis is a pathogen causing tuberculosis, and the surface of the mycobacterium tuberculosis carries a large amount of negative charges. Once the mycobacterium tuberculosis with negative charges on the surface is in contact with a binder containing a large amount of positive charges, the surface of the mycobacterium tuberculosis can be rapidly wrapped by the binder to form a firm adhesion layer, and the problem of chip falling is not prone to occurring in the dyeing and subsequent detection process.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having severe renal impairment.

The present disclosure relates to the administration to a human patient of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride or a molar equivalent amount of bupropion in the free base form or another salt form; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide or a molar equivalent amount of dextromethorphan in the free base form or another salt form, to treat neurological and psychiatric conditions, such as agitation, associated with Alzheimer's disease and / or to reduce the recurrence of agitation in Alzheimer's disease.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

This disclosure relates to dosage forms comprising: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of dextromethorphan; and 2) about 25-35 mg, about 29-31 mg, about 30 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan. In some embodiments, a dosage form as described herein is free of a Compound I and Compound II. In some embodiments, a dosage form may contain 0.5 ng to 750 ng of Compound I, 0.5 ng to 750 ng of Compound II, or a combination thereof. These dosage forms may be used to treat various neurological and psychiatric conditions, including major depressive disorder, agitation associated with Alzheimer's disease, and nicotine addiction.

This disclosure relates to a method of treating depression and / or reducing suicide risk, comprising administering a combination of about 90 mg to about 120 mg of bupropion chloride (or another molar equivalent of bupropion) and about 40 mg to about 50 mg of dextromethorphan hydrobromide (or another molar equivalent of dextromethorphan). This combination can be administered twice daily to individuals suffering from severe depression and scoring 3 or higher on the Suicide Proneness Item of the Montgomery-Aussberg Depression Rating Scale (MADRS-SI).